Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 05/12/2025 at 07:05, 6 months 23 days ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
PRESS RELEASE

published on 05/12/2025 at 07:00, 6 months 23 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 04/01/2025 at 07:05, 8 months 3 days ago

Newron Pharmaceuticals Reports 2024 Financial Results, Previews 2025

Financial Results Evenamide Development Schizophrenia Treatment Licensing Agreements Outlook 2025
PRESS RELEASE

published on 04/01/2025 at 07:00, 8 months 3 days ago

Newron presents 2024 financial results and provides 2025 outlook
Newron Pharmaceuticals presents 2024 financial results and 2025 outlook, focusing on evenamide development for schizophrenia treatment and strategic licensing agreements

Financial Results Newron Pharmaceuticals Evenamide Licensing Agreements 2025 Outlook
BRIEF

published on 03/24/2025 at 17:50, 8 months 11 days ago

Newron Pharmaceuticals Nominates Dr. Chris Martin as Independent Chairman

Board Of Directors Newron Pharmaceuticals Chris Martin Biopharma Leadership Schizophrenia Therapy
PRESS RELEASE

published on 03/24/2025 at 17:45, 8 months 11 days ago

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Newron Pharmaceuticals S.p.A. proposes Chris Martin, ex-CEO of ADC Therapeutics, as Independent Chairman succeeding Dr. Köstlin after 12 years. Martin an experienced biopharma leader

Chairman Biopharma Newron Pharmaceuticals Chris Martin ADC Therapeutics
BRIEF

published on 01/09/2025 at 07:05, 10 months 26 days ago

Newron and Myung In Pharm License Agreement for Evenamide in South Korea

Phase III Trial CNS Therapies Evenamide Schizophrenia Treatment License Agreement
PRESS RELEASE

published on 01/09/2025 at 07:00, 10 months 26 days ago

Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. and Myung In Pharm enter license agreement for evenamide in South Korea, aiming to develop innovative treatment option for schizophrenia patients

Newron Pharmaceuticals Evenamide License Agreement South Korea Myung In Pharm
BRIEF

published on 12/13/2024 at 07:05, 11 months 22 days ago

Newron and EA Pharma Sign License Agreement for Evenamide in Asia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment License Agreement EA Pharma
PRESS RELEASE

published on 12/13/2024 at 07:00, 11 months 22 days ago

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron Pharmaceuticals S.p.A. and EA Pharma (a subsidiary of Eisai Co., Ltd.) have signed a license agreement for evenamide in Japan and other Asian territories, aiming to address unmet medical needs in patients with schizophrenia

Schizophrenia Newron Pharmaceuticals Evenamide License Agreement EA Pharma

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE